Institut Pasteur Korea – Hakim Djaballah, CEO
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Institut Pasteur Korea is conceptualized around the virtual “genome to drugs” pipeline. The goal of IP-Korea is to actively implement post-genomic approaches into accelerated drug discovery. Accordingly, IP-Korea is situated at the very fault line between basic research and application.
The positioning of our institute is in good accordance with the Pasteurian tradition and mission. During its long history Institut Pasteur in Paris has been able to combine scientific achievements with their application in public health. This has improved the lives of millions of patients over the last 130 years, and has earned Institut Pasteur 10 Nobel prizes.
To extend and build on these achievements, IP-Korea is the first to develop a technology-based approach to therapeutic development in the areas of infectious and chronic diseases.
Strategically it combines its strength in biomedical research with Korean expertise in Information and Chemical technologies.
The result is the consequent implementation of visualization and imaging technology in analyzing disease models, accelerating both drug discovery and basic research.
Contact details
Address: 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Tel: +82 31 8018 8000
Fax: +82 31 8018 8010
Email: ipkorea@ip-korea.org
www.ip-korea.org
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Song In-Keum, chairman of the Korean Medical Devices Industry Association (KMDIA), discusses current opportunities offered by Korea’s growing medtech industry. What have been your priorities since you became the…
The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about…
Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at…
The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current…
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans. What differentiates P&K Skin…
Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the…
The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases. As…
The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research…
The director general of Korea’s Bureau of Health Industry explains what has led to Korea’s excellent healthcare system, and the competitiveness of the country’s pharmaceutical sector. Can you provide our…
Jung Kee-Taig, president of the Korea Health Industry Development Institute (KHIDI), outlines his “Health Economy 2030” for Korea, and highlights the institute’s domestic and international collaborations. KHIDI aims to…
Prior to founding Bioneer, Park Han-Oh spent a number of years working at KRIBB. Today he speaks about the company’s latest breakthrough technology in DNA synthesis and his outlook for…
See our Cookie Privacy Policy Here
